Top Markets
#1 Black Phoenix Black Phoenix +355.52%
#2 Glidr Glidr +84.34%
#3 Gold Park Gold Park +55.17%
#4 Akedo Akedo +48.78%
#5 Acurast Acurast +29.95%
#6 BasedHype BasedHype +23.54%
#7 Cryptopia Cryptopia +21.54%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +21.11%
#9 Avantis Avantis +20.16%
#10 Quantum Resistant Ledger Quantum Resistant Ledger +15.50%
Coin of the day
Black Phoenix Black Phoenix
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Histogen Inc. Histogen Inc.

Histogen Inc.

HSTO
Rang in aandelen #40868
Histogen Inc. operates as a clinical-stage biotechnology company, focusing on... Histogen Inc. operates as a clinical-stage biotechnology company, focusing on the development of novel, stem cell-free biologic products derived from its proprietary hypoxia-generated growth factor technology platform. Among its offerings is HST-003, a human extracellular matrix, currently undergoing Phase 1/2 clinical trials to mend articular cartilage defects in the knee. Additionally, the company is advancing HST-004, a cell-conditioned media solution designed for spinal disc repair, and Emricasan, an orally active pan-caspase inhibitor targeting COVID-19 treatment. In its preclinical pipeline, Histogen is developing CTS-2090 and CTS-2096. These are selective caspase-1 inhibitors formulated to suppress inflammasome activation and intervene in a range of inflammation-mediated conditions. Founded in 2007, Histogen Inc. maintains its headquarters in San Diego, California.
Aandeelprijs
$0.02765
Laatst gesynchroniseerd: 2024-12-23
Marktkapitalisatie
$69.04K
Verandering (1 dag)
0.00%
Verandering (1 jaar)
0.00%
Land
US
Handel Histogen Inc. (HSTO)

Categorie

Healthcare
P/S-ratio voor Histogen Inc. (HSTO)
P/S-ratio op August 2026 TTM: 0.02
Volgens de meest recente financiële rapporten en aandelenkoers van Histogen Inc. is de huidige P/S-ratio (TTM) 0.02. Eind 2021 had het bedrijf een P/S-ratio van 1.38.
P/S-ratiohistoriek voor Histogen Inc. van 2011 tot 2026
P/S-ratio aan het einde van elk jaar
Jaar P/S-ratio Wijzigen
2026 (TTM) 0.02 -67.57%
2022 0.07 -94.87%
2021 1.38 313.79%
2020 0.33 -19.32%
2019 0.41 163.81%
2018 0.16 -58.10%
2017 0.37 -97.50%
2016 14.94 0.00%
2015 0.00 0.00%
2014 0.00 0.00%
2013 0.00 0.00%
2012 0.00 0.00%
2011 0.00 0.00%
P/S-ratio voor vergelijkbare bedrijven of concurrenten
Bedrijf P/S-ratio Verschil in P/S-ratio Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
9.88 43,427.75%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.30 45,287.67%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
4.98 21,835.24%
BE